Pagulayan, Kathleen F.
Petrie, Eric C.
Cook, David G.
Hendrickson, Rebecca C.
Rau, Holly
Reilly, Melissa
Mayer, Cindy
Meabon, James S.
Raskind, Murray A.
Peskind, Elaine R.
Kleinhans, Natalia
Funding for this research was provided by:
U.S. Department of Veterans Affairs (IK2CX000516, I01 RX000521)
University of Washington Royalty Research Fund (none)
Article History
First Online: 5 December 2018
Compliance with ethical standards
:
: Author Raskind has received consultant fees from Takeda Pharmaceuticals and Merck Pharmaceuticals. Author Peskind has received consultant fees from Takeda, Merck, Aramis, and Eli Lilly. Author Meabon is Chief Operations Officer for Neurogenix Pharmaceuticals, Inc. Authors Cook, Hendrickson, Kleinhans, Mayer, Pagulayan, Petrie, Rau, and Reilly declare that they have no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.